Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1977 Feb;11(2):185–190. doi: 10.1128/aac.11.2.185

Pharmacological and Clinical Study of Bacampicillin in Acute Peritonsillitis–a Comparison with Ampicillin

Hans O Hallander 1, Anders Flodström 1, Jan Sjövall 1
PMCID: PMC351950  PMID: 322607

Abstract

The pharmacological and clinical properties of bacampicillin in three dosage groups were studied in 66 hospitalized patients with unilateral acute peritonsillitis in a comparison with ampicillin. Bacampicillin is a new semisynthetic aminopenicillin which is rapidly converted to ampicillin but is better absorbed. Both drugs were given orally. The mean individual peak serum levels achieved with 200, 400, and 800 mg of bacampicillin in the first morning dose were 4.9, 6.8, and 11.9 mg/liter, respectively, with an almost linear dose response. The peak level of 800 mg of bacampicillin was significantly higher than the 6.8 mg/liter noted after a nearly equimolar dose of 500 mg of ampicillin. A linear relationship was also seen between dose and area under the serum concentration-time curve. Preliminary antibiotic concentration studies in five patients indicated therapeutic levels in peritonsillar pus. Beta-streptococci alone or in combination with anaerobes were isolated from about half of the abscesses, whereas anaerobes were isolated from the other half. Treatment was supplemented by surgical procedures in the majority of cases. The clinical effect was good in all treatment groups, with only one relapse. All beta-streptococci were eliminated during therapy. The total number of gastrointestinal side effects was significantly lower in patients treated with bacampicillin, although the difference in frequency of diarrhea alone was not significant.

Full text

PDF
185

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodin N. O., Ekström B., Forsgren U., Jalar L. P., Magni L., Ramsay C. H., Sjöberg B. Bacampicillin: a new orally well-absorbed derivative of ampicillin. Antimicrob Agents Chemother. 1975 Nov;8(5):518–525. doi: 10.1128/aac.8.5.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clayton J. P., Cole M., Elson S. W., Ferres H. BRL.8988 (talampicillin), a well-absorbed oral form of ampicillin. Antimicrob Agents Chemother. 1974 Jun;5(6):670–671. doi: 10.1128/aac.5.6.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daehne W., Frederiksen E., Gundersen E., Lund F., Morch P., Petersen H. J., Roholt K., Tybring L., Godtfredsen W. O. Acyloxymethyl esters of ampicillin. J Med Chem. 1970 Jul;13(4):607–612. doi: 10.1021/jm00298a005. [DOI] [PubMed] [Google Scholar]
  4. Flodström A., Hallander H. O. Microbiological aspects on peritonsillar abscesses. Scand J Infect Dis. 1976;8(3):157–160. doi: 10.3109/inf.1976.8.issue-3.06. [DOI] [PubMed] [Google Scholar]
  5. Gorbach S. L., Bartlett J. G. Anaerobic infections (third of three parts). N Engl J Med. 1974 Jun 6;290(23):1289–1294. doi: 10.1056/NEJM197406062902305. [DOI] [PubMed] [Google Scholar]
  6. Hallander H. O., Flodström A., Holmberg K. Influence of the collection and transport of specimens on the recovery of bacteria from peritonsillar abscesses. J Clin Microbiol. 1975 Dec;2(6):504–509. doi: 10.1128/jcm.2.6.504-509.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jalling B., Malmborg A. S., Lindman A., Boréus L. O. Evaluation of a micromethod for determination of antibiotic concentrations in plasma. Eur J Clin Pharmacol. 1972 Jun;4(3):150–157. doi: 10.1007/BF00561138. [DOI] [PubMed] [Google Scholar]
  8. Knudsen E. T., Harding J. W. A multicentre comparative trial of talampicillin and ampicillin in general practice. Br J Clin Pract. 1975 Oct;29(10):255–passim. [PubMed] [Google Scholar]
  9. Maesen F. P., Beeuwkes H., Davies B. I., Buytendijk H. J., Brombacher P. J., Wessman J. Bacampicillin in acute exacerbations of chronic bronchitis--a dose-range study. J Antimicrob Chemother. 1976 Sep;2(3):279–285. doi: 10.1093/jac/2.3.279. [DOI] [PubMed] [Google Scholar]
  10. Rozencweig M., Staquet M., Klastersky J. Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin Pharmacol Ther. 1976 May;19(5 Pt 1):592–597. doi: 10.1002/cpt1976195part1592. [DOI] [PubMed] [Google Scholar]
  11. Wilcox J. B., Brogden R. N., Avery G. S. Pivampicillin: a preliminary report of its pharmacokinetic properties and therapeutic efficacy. Drugs. 1973;6(2):94–103. doi: 10.2165/00003495-197306020-00003. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES